Studying Pathways of Resistance in KRAS-driven Cancers

Inclusion Criteria:

Cohort 1A- Liquid Biopsy

Participants older than 18 years old at the time of consent or age of majority for residential state.
Demonstration of having advanced KRAS G12C positive cancer.
Systemic progression (not CNS only progression) within the past 30 days, having previously been treated with a therapeutic, targeting the specific KRAS mutation.
Patient must not have started a new line of therapy before signing the informed consent form.
Willingness to provide a blood specimen prior to the initiation of a new line of treatment.
Willingness to provide clinical and medical information to the study team as required.
Ability to read, write and communicate in English.
Ability to sign a web-based informed consent form.

Cohort 1B- Data Sharing

Participants older than 18 years old at the time of consent or age of majority for residential state.
Demonstration of having advanced KRAS G12C positive cancer.
Systemic progression (not CNS only progression) after being treated with a therapeutic targeting the specific KRAS mutation.
Patient must have prior tumor genotyping available (tissue or plasma) after progression on therapeutic targeting the specific KRAS mutation.
Willingness to provide clinical and medical information to the study team as required.
Ability to read, write and communicate in English.
Ability of the participant or legally authorized representative (LAR) to sign a web-based informed consent form.

Exclusion Criteria:

Participants who are unable to comply with the study procedures.
Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.
Participants who have previously enrolled to the study.